Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus by Piga, Matteo et al.
RESEARCH ARTICLE Open Access
Failure to achieve lupus low disease activity
state (LLDAS) six months after diagnosis is
associated with early damage accrual in
Caucasian patients with systemic lupus
erythematosus
Matteo Piga*† , Alberto Floris†, Giulia Cappellazzo, Elisabetta Chessa, Mattia Congia, Alessandro Mathieu
and Alberto Cauli
Abstract
Background: The aim was to assess the attainability and outcome of the lupus low disease activity state (LLDAS) in
the early stages of systemic lupus erythematosus (SLE).
Methods: LLDAS prevalence was evaluated at 6 (T1) and 18 (T2) months after diagnosis and treatment initiation (T0) in a
monocentric cohort of 107 (median disease duration 9.7 months) prospectively followed Caucasian patients with SLE.
Reasons for failure to achieve LLDAS were also investigated. Multivariate models were built to identify factors associated
with lack of LLDAS achievement and to investigate the relationship between LLDAS and Systemic Lupus International
Collaboration Clinics (SLICC)/Damage Index (SDI) accrual.
Results: There were 47 (43.9%) patients in LLDAS at T1 and 48 (44.9%) at T2. The most frequent unmet LLDAS criterion
was prednisolone dose >7.5 mg/day (83% of patients with no LLDAS at T1). Disease manifestations with the lowest
remission rate during follow up were increased anti-double-stranded DNA (persistently present in 85.7% and 67.5% of
cases at T1 and T2, respectively), low serum complement fractions (73.2% and 66.3%) and renal abnormalities (46.4%
and 28.6%). Renal involvement at T0 was significantly associated with failure to achieve LLDAS both at T1 (OR 7.8,
95% CI 1.4–43.4; p = 0.019) and T2 (OR 3.9, 95% CI 1.4–10.6; p = 0.008). Presence of any organ damage (SDI ≥1) at T2
was significantly associated with lack of LLDAS at T1 (OR 5.0, 95% CI 1.5–16.6; p = 0.009) and older age at diagnosis
(OR 1.05 per year, 95% CI 1.01–1.09; p = 0.020).
Conclusion: LLDAS is a promising treatment target in the early stages of SLE, being attainable and negatively associated
with damage accrual, but it fit poorly to patients with renal involvement.
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Background
Systemic lupus erythematosus (SLE) is a chronic multi-
system disease, characterized by wide heterogeneity in
clinical presentation, course and responsiveness to
therapy [1, 2]. Despite significant advances in the under-
standing of the pathophysiology and optimization of
medical care [3, 4], patients with SLE have an age-
standardized mortality rate of 3.2 per 1 million people
[5] and carry a risk of progressive organ damage accrual
and reduced health-related quality of life [6, 7].
The treat-to-target (T2T) approach, successfully applied
in rheumatoid arthritis and other non-rheumatic condi-
tions, is a therapeutic strategy aiming to improve disease
outcomes through the achievement of a pre-specified goal
[8]. An international task force has recently suggested ap-
plying the T2T strategy in SLE, recommending that the
treatment target should be remission or, where this cannot
be reached, the lowest possible disease activity [9]. Many
different definitions of remission, none of them generally
accepted, are currently available in the literature and many
controversial issues have to be clarified, such as its real
attainability as a treatment target in clinical practice
[10–12]. On the one hand, a framework for definition
of remission in SLE (DORIS) has been recently set up
by an international expert group [12]. On the other
hand, a composite definition of minimal acceptable
disease activity, the lupus low disease activity state
(LLDAS), has been proposed by the Asia-Pacific
Lupus Collaboration (APLC) [13]. LLDAS is based on
the following criteria: (1) SLE Disease Activity Index
2000 (SLEDAI-2K) ≤4, with no activity in major
organ systems (renal, central nervous system, cardio-
pulmonary, vasculitis, gastrointestinal, haemolytic an-
aemia fever); (2) no new lupus disease activity
compared with the previous assessment; (3) Safety of
Estrogen in Lupus Erythematosus National Assess-
ment (SELENA)-SLEDAI physician global assessment
(PGA) ≤1; (4) current prednisolone (or equivalent)
dose ≤7.5 mg daily; and (5) well-tolerated standard
maintenance doses of immunosuppressive drugs and
approved biological agents [13].
Early damage was demonstrated to be associated with
lower 10-year survival, such that patients with initial dam-
age have a fourfold higher mortality rate compared to
those with no early damage [14]. In order to be considered
a valid treatment target, LLDAS should be proved as being
protective against damage accrual in the early SLE stages.
However, LLDAS prevalence and its association with
damage have been investigated in a few longstanding
SLE cohorts with no homogeneous disease duration
[13, 15, 16] and therefore no data are currently avail-
able on its potential role as an early treatment target.
This study primarily aimed to assess the frequency of
LLDAS achievement and its association with early
damage accrual in a homogeneous cohort of Caucasian
patients with SLE prospectively assessed during the first
18 months of treatment after diagnosis. The secondary
aim was to identify the main reasons for failure to
achieve LLDAS.
Methods
Patients
Data from patients included in the Cagliari (Italy) SLE
cohort [17] between 1 January 2006 and 31 December
2016 were used for this study. Inclusion criteria were: (a)
SLE diagnosed according to the revised 1997 American
College of Rheumatology (ACR) criteria [18]; (b) starting
the first treatment for SLE at enrolment in the Cagliari
cohort; (c) moderate to severe disease activity (SLEDAI-
2K ≥6) at baseline; (d) at least quarterly visits during the
study interval; and (e) age ≥18 years.
Retrospective analysis of prospectively collected data
was performed, reviewing medical records and clinical
files. Baseline was fixed at the time of diagnosis, which
corresponded to treatment initiation (T0). No specific
recommendations are currently available on the appro-
priate time to assess the target achievement in a T2T
strategy for SLE [9]. In order to assess LLDAS as a goal
for initial treatment we set the primary study endpoint
at 6 months (T1), according to the average induction
therapy duration recommended for severe disease mani-
festations, such as glomerulonephritis [19]. Eighteen
months (T2) was considered as an appropriate time to
evaluate the effect of maintenance treatment and the
early damage accrual [14, 20].
Patient assessment
Demographic factors including gender, age at onset and
diagnosis were collected. Disease onset was defined as the
time of appearance of the first clinical classification criter-
ion. Disease duration was the time period between disease
onset and diagnosis. The number of 1997 ACR criteria pre-
sented from disease onset up to the baseline was recorded.
At baseline, antinuclear antibodies (ANA) (tested by indir-
ect immunofluorescence (IIF), using Hep2 cell substrate,
positivity was defined as a titre >1:160), anti-Ro/SSA,
anti-La/SSB, anti-Sm, anti-RNP, lupus anticoagulant, antic-
ardiolipin (IgG nv <12 GPL; IgM nv <12 MPL) and anti-
B2-glicoprotein1 (IgG nv <12 GPL; IgM nv <12 MPL)
antibodies were assessed. Anti-dsDNA antibodies (by Farr
assay; nv <10 IU/mL) and C3 (nv 90–180 mg/dL), C4 (nv
10–40 mg/dL) serum complement fractions were quarterly
tested.
At each visit, disease activity was assessed using the
SLEDAI-2K score and the PGA (0–3) [21]. Damage
accrual was assessed at 18 months by the SDI [22] and
the possible attribution to corticosteroids was done ac-
cording to a previous definition [23]. Ongoing use and
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new prescription of corticosteroids, anti-malarial and
immunosuppressant drugs (azathioprine, methotrexate,
mycophenolate mofetil, cyclosporine A, cyclophospha-
mide or rituximab) were assessed at every visit. Average
daily dose of prednisolone (or equivalent) was recorded
for each patient at every study follow-up visit.
Data analysis
Normally and non-normally distributed variables were
summarized using mean ± standard deviation (SD) and
median with interquartile range (IQR), respectively.
Univariate and multivariate analysis were performed to
evaluate potential factors associated with failure to
achieve LLDAS. Univariate analysis was performed using
the two-sample Student t test or Mann–Whitney test for
quantitative variables, and the Chi-square test or Fisher's
exact test for qualitative variables. Variables with a p
value <0.1 on univariate analysis were included in a
multivariate model for stepwise logistic regression. The
odds ratio (OR) with 95% confidence interval (95% CI)
was calculated.
To assess the association between lack of LLDAS
achievement and damage development, a logistic regres-
sion model was created. Occurrence of any damage (SDI
≥1) at 18 months was included as the dependent variable,
whereas age, disease duration, male gender, average daily
steroids dosage, renal involvement, use of anti-malarial or
immunosuppressant drugs [24] and failure to achieve
LLDAS at T1 and at T2 comprised the independent
variables. Statistical significance was set at a p value <0.05.
MedCalc® statistical software (Mariakerke, Belgium) was
used.
Results
Patients
Overall, 178 new patients joined the Cagliari (Italy) SLE
cohort during the study interval. The study cohort con-
sisted of 107 (60.1%). The relevant features of Caucasian
patients with SLE who fulfilled the inclusion criteria for
study enrolment are summarized in Table 1. Regarding
excluded patients, 31 were diagnosed elsewhere and
were already on treatment at the time of enrolment, 25
had no quarterly follow up, 7 were younger than 18 years
and 6 had SLEDAI-2K <6 at baseline.
LLDAS achievement
At T1 (6 months), LLDAS was achieved by 47 (43.9%) pa-
tients. Focusing on unmet criteria for LLDAS in the
remaining 60 (56.1%) patients: 50 (83.3%) were not on
prednisolone ≤7.5 mg daily and 29 of them had SLEDAI-
2K ≤4 and PGA ≤1; 7 (11.7%) did not have SLEDAI-2K ≤4
or PGA ≤1 with prednisolone dosage ≤7.5 mg/day, 3
(5.0%) experienced new manifestation (Fig. 1).
Table 1 Demographic, clinical and serological features at baseline
Demographic features Value
Female gender, n (%) 96 (89.7%)
Caucasian, (%) 107 (100%)
Onset age, median (IQR) years 31.3 (25.0–42.6)
Age at diagnosis, median (IQR) years 34.3 (26.5–43.7)
Disease duration at diagnosis, median (IQR) months 9.7 (6.0–27.6)
ACR 1997 clinical criteria
Malar rash, n (%) 29 (27.1%)
Discoid rash, n (%) 7 (6.5%)
Photosensitivity, n (%) 26 (24.3%)
Oral ulcers, n (%) 11 (10.3%)
Arthritis, n (%) 96 (89.7%)
Serositis, n (%) 32 (29.9%)
Renal disorders, n (%) 27 (25.2%)
Class Va 4 (3.7%)
Class IVa 8 (7.5%)
Class IIIa 6 (5.6%)
Class IIa 3 (2.8%)
Not biopsy proven 6 (5.6%)
Neurologic disorders, n (%) 3 (2.8%)
Haematological disorders, n (%) 61 (57.0%)
Disease activity
SLEDAI-2K score, median (IQR) 10.0 (8.0-15.8)
SLICC Damage Index, median IQRb 0 (0-0)
Serological features
ANA, n (%) 106 (99.1%)
Anti-dsDNA, n (%) 78 (72.9%)
Anti-Sm, n (%) 19 (17.8%)
Anti-RNP, n (%) 27 (25.2%)
Anti-SSA, n (%) 46 (43.0%)
Anti-SSB, n (%) 13 (12.1%)
Any aPLs 26 (24.3%)
Treatment
PDN dose at T0, median (IQR) mg/day 15.0 (6.5–26.9)
PDN dose T0–T2, median (IQR) mg/day 10.4 (5.7–18.2)
Anti-malarial drug, n (%) 67 (62.6%)
Immunosuppressant drug, n (%) 68 (63.5%)
Methotrexate, n (%) 24 (22.4%)
Cyclophosphamide, n (%) 21 (19.6%)
Azathioprine, n (%) 17 (15.9%)
Cyclosporine A, n (%) 5 (4.7%)
Mycophenolate mofetil, n (%) 2 (1.9%)
Rituximab, n (%) 1 (0.9%)
ACR American College of Rheumatology, ANA antinuclear antibodies, aPLs
positivity for lupus anti-coagulant (LAC) and/or anticardiolipin and/or antiBeta2-
GPI antibodies, PDN prednisolone (or equivalent), SLEDAI-2K, Systemic Lupus
Erythematosus Disease Activity Index 2000, SLICC Systemic Lupus International
Collaboration Clinics ()/SLICC
aAccording to the International Society of Nephrology/Renal Pathology Society
(ISN/RPS) 2003 classification of lupus nephritis
bAt diagnosis the SLICC Damage Index is equal to 0 by definition
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At T2 (18 months), 48 (44.9%) patients were in
LLDAS; 33 of them achieved LLDAS at T1 and were still
in this condition at T2, whereas 15 reached LLDAS
within the interval between T1 and T2 for the first time.
Out of 59 (55.1%) patients who were not in LLDAS at
T2, 45 had never been in LLDAS and 14 were in LLDAS
at T1 but no longer at T2 (Fig. 2). Major reasons for loss
of LLDAS in these 14 patients were the onset of new
disease activity manifestations in 7 (50.0%) patients (3
with articular, 3 with cutaneous and 1 with vasculitis
manifestations), intolerance of drug treatment in 5
patients (35.7%) and a new finding of positivity for anti-
dsDNA or low complement in 2 patients (14.3%).
Persistently active SLEDAI items
Individual SLEDAI-2K items were grouped into neuro-
logic, vasculitis, arthritis, renal, myositis, mucocutane-
ous, serositis, low complement, increased anti-dsDNA
and haematologic disorders. SLEDAI-2K items with
worse remission rates were high anti-dsDNA concentra-
tion, complement consumption and renal abnormalities.
Increased anti-dsDNA levels were still present in 85.7%
and 67.5% of patients at T1 and T2 respectively, low
complement in 73.2% and 66.3% of patients and renal
disorders in 46.4% and 28.6% of patients (Fig. 3).
Factors associated with failure to achieve LLDAS
On univariate analysis, the following factors recorded at
baseline were significantly associated with failure to
achieve LLDAS at T1: renal involvement (25 (41.7%) vs
2 (4.3%); p < 0.001)), higher SLEDAI-2K score (median
13.0 (9.0–18.0) vs 8 (7.2–10.0); p < 0.001)), positive
(>10UI/mL) anti-dsDNA antibodies (49 (81.7%) vs 29
(61.7%); p = 0.013), lower serum C3 (median 65.5 (40.1–
80.5) vs 82.0 (67.0–90.8) mg/dL; p = 0.002) and C4
values (10.0 (4.0–13.0) vs 13.0 (10.0–16.0) mg/dL; p =
0.013), higher prednisolone dose (median 25 (14–38) vs
Fig. 1 Analysis of the main causes of lack of lupus low disease activity state (LLDAS) achievement. SLEDAI-2K, Systemic Lupus Erythematosus
Disease Activity 2000; PGA, physician global assessment; PDN, prednisolone (or equivalent)
Fig. 2 Patients who were in lupus low disease activity state (LLDAS) and
patients who were not in LLDAS (no-LLDAS) at 18 months (T2).
Persistent LLDAS, patients who were in LLDAS at 6 months (T1) and at
T2; No-LLDAS→ LLDAS, patients who achieved LLDAS within the T1–T2
interval; Persistent no-LLDAS, patients who never achieved LLDAS;
No-LLDAS← LLDAS, patients who were in LLDAS at T1 but not at T2
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8 (5–15) mg/day; p < 0.001) and immunosuppressant
drug use (45 (75.0%) vs 23 (48.9%); p = 0.010). On multi-
variate analysis renal involvement (OR 7.8, 95% CI 1.4–
43.4; p = 0.019) and C4 level (OR 0.91, 95% CI 0.83–
0.99; p = 0.036) were confirmed to be associated with
failure to achieve LLDAS (Table 2).
Demographic, clinical and serological variables at base-
line were also analysed as potential predictors of lack of
LLADS at T2. On univariate analysis renal involvement
(21 (36%) vs 6 (13%); p = 0.016), discoid rash (7 (11.9%)
vs 0; p = 0.007), any aPLs (10 (16.9%) vs 16 (33.3%); p =
0.016) and average prednisolone dosage (median 12.5
(6.7–21.6) vs 8.0 (5.0–14.4) mg/day; p = 0.0159) were
associated with no LLDAS achievement at 18 months.
On multivariate analysis, renal involvement was the only
factor independently associated with failure to achieve
LLDAS at T2 (OR 3.9, 95% CI 1.4–10.6; p = 0.008).
LLADS and early damage
After 18 months since diagnosis (T2), 23 patients out of
107 (21.5%) had SDI≥1 (range 0-3). Overall, 27 SDI
items of damage were recorded in 23 patients at T2: 9
were definitely steroid-related (7 with cataracts, 1 with
osteoporosis with vertebral collapse or fractures, 1 with
muscle atrophy), 8 possibly steroid-related (5 with cogni-
tive impairment, 1 with angina or coronary disease) and 9
independent of corticosteroid use (2 with cerebrovascular
accident, 2 with pleural fibrosis, 2 with pulmonary fibrosis,
1 with tissue loss, 1 with proteinuria >3.5 g/24 h, 1 with
valvular disease, 1 with thrombosis, 1 with erosive arthritis
and 1 with malignancy).
Out of 23 patients with SDI ≥1 at 18 months, 19
(82.6%) had not achieved LLDAS at T1 and 18
(78.3%) at T2. In the logistic regression model failure to
achieve LLDAS at T1 (OR 5.0 95% CI 1.5–16.6; p =
0.009) and age at diagnosis (OR 1.05 per year; 95% CI
1.01–1.09; p = 0.020) were independently associated with
the presence of any damage at T2 (Table 3).
Discussion
In our study cohort 44% and 45% of patients were in
LLDAS 6 and 18 months after treatment initiation, re-
spectively. Despite a seemingly overall stable LLDAS
rate, the dynamic nature of this condition was demon-
strated. In fact, 14% of subjects first achieved LLDAS
between the 6th and 18th month, whereas 13% of patients
who were in LLDAS after 6 months of treatment lost
LLDAS within the following 12 months. Golder et al.
found that in a in a cross-sectional assessment, 44% of
1846 patients with SLE and a mean disease duration of
8.6 years did not achieve LLDAS [15]. Franklyn et al., in
an SLE cohort with mean disease duration of 7.1 years,
observed that 88% of patients achieved LLDAS at least
once and that 38% of patients had this status for more
Fig. 3 Frequency (percentage) of manifestations still identified at 18 months (T2) and respective remission rate. Purple, frequency (percentage) of
manifestations recorded at T0 and still present at T2. Dark blue, manifestations that were in remission at 6 months (T1). Light blue, manifestations
that were recorded as in remission for the first time at T2. Below the bars the global remission rate is reported
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than half of the follow-up duration [13]. These data
suggest that the minimal disease activity, according to
the LLDAS criteria, would be a more applicable goal in
a T2T strategy than remission, according to the current
definition [12, 25], especially in early disease stages [10].
Actually, Wilhem et al. observed that the median time
to achieve durable remission, classified in four subtypes
according to the principle proposed by the DORIS
group, ranged between 1.8 and 11.0 years [10].
In this study, the most frequent reason for failure to
achieve LLDAS 6 months after therapy initiation was
daily prednisolone dosage >7.5 mg (83% of no LLDAS).
In the study by Golder et al., prednisolone dosage was
an unmet criterion in 57% of patients who did not
achieve LLDAS [15]. In a study aiming to test the con-
struct validity of LLDAS compared to expert opinion,
disagreement was mainly due to low disease activity
classification of patients with prednisolone daily dosage
Table 2 Demographic, clinical and serological factors associated with failure to achieve LLDAS at T1
Univariate analysis Multivariate analysis
No LLDA at T1 (n = 60) LLDAS at T1 (n = 47) p value Odds ratio p value
Demographic features
Male, n (%) 6 (10.0%) 5 (10.6%) 1.00
Onset age, median (IQR) years 32.3 (25.7–43.0) 29.2 (24.4–39.8) 0.221
Diagnosis age, median (IQR) years 36.9 (28.2–45.1) 31.2 (25.6–40.6) 0.152
Disease duration, median (IQR) months 9.0 (5.0–12.3) 10.6 (6.1–30.6) 0.340
Clinical features
Malar rash, n (%) 15 (25.0%) 14 (29.8%) 0.580
Discoid rash, n (%) 4 (6.7%) 3 (6.4%) 1,000
Photosensitivity, n (%) 16 (26.7%) 10 (21.3%) 0.519
Oral ulcers, n (%) 7 (11.7%) 4 (8.5%) 0.752
Arthritis, n (%) 54 (90.0%) 42 (89.4%) 1.00
Serositis, n (%) 19 (31.7%) 13 (27.7%) 0.653
Renal disorder, n (%) 25 (41.7%) 2 (4.3%) <0.001 7.8 (1.41–43.4) 0.019
Neurologic disorder, n (%) 3 (5.0%) 0 0.254
Haematological disorders, n (%) 37 (61.7%) 24 (51.1%) 0.272
SLEDAI-2K, median (IQR) score 13 (9.0-18.0) 8 (7.2–10.0) <0.001 - -
Serological features
ANA, n (%) 59 (98.3%) 47 (100%) 1.00
Anti-dsDNA, n (%) 49 (81.7%) 29 (61.7%) 0.013 - -
Anti-dsDNA, median (IQR) UI/mL 114 (46–2069) 106 (31–191) 0.057
Anti-Sm, n (%) 11 (18.3%) 8 (17.0%) 0.860
Anti-RNP, n (%) 17 (28.3%) 10 (21.3%) 0.404
Anti-SSA, n (%) 23 (38.3%) 23 (48.9%) 0.272
Anti-SSB, n (%) 5 (8.3%) 8 (17.0%) 0.172
Any aPLs, n (%) 15 (25.0%) 11 (23.4%) 0.971
C3, median (IQR) mg/dL 65.5 (40.1–80.5) 82.0 (67.0–90.8) 0.002 - -
C4, median (IQR) mg/dL 10.0 (4.0–13.0) 13.0 (10.0–16.0) 0.013 0.91 (0.83–0.99) 0.036
Therapy
Anti-malarials drugs, n (%) 41 (68.3%) 26 (55.3%) 0.167
Immunosuppressant drugs, n (%) 45 (75.0%) 23 (48.9%) 0.010 - -
PDN dose, median (IQR) mg/day 25.0 (13.7–37.5) 8.0 (5.0–14.8) <0.001 1.04 (0.99–1.1) 0.073
Boxes are empty where statistical analysis was not applied. In the present logistic regression model the Systemic Lupus Erythematosus Disease Activity Index 2000
(SLEDAI-2 k) score was removed
LLDAS lupus low disease activity state, No LLDAS failure to achieve LLDAS, aPLs positivity for lupus anticoagulant (LAC) e/o aCL e/o Beta2-GPI antibodies, PDN
prednisolone (or equivalent)
Numbers in bold indicate statistical significance for p < 0.05
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≥7.5 mg (up to 10 mg/day), suggesting that such a
higher dose was deemed acceptable by several experts
who were interviewed [26]. Nevertheless, the lowest cor-
ticosteroid dose to be considered safe has not been
definitely identified. Prednisolone >5 mg/day was re-
ported to be associated with greater risk of osteoporosis,
infections, cataracts and metabolic and cardiovascular
disorders [27–29]. Tharmer et al. observed that the risk
of damage accrual in patients with SLE did not substan-
tially increase with prednisolone cumulative doses
<180 mg/month (equivalent to 6 mg/day) [30]. In our
cohort, damage was definitely attributable to steroid use
in 40% of cases. Gladman et al. reported that 58% and
80% of the damage accrued in the first year after diagno-
sis and in later disease, respectively, could be described
as “possibly or definitely” steroid-related [23]. In con-
trast, a larger proportion of early damage was related to
early inflammatory organ damage [24]. In our study we
found that failure to achieve early LLDAS (at 6 months)
and older age at diagnosis, but not corticosteroid daily
dose, were independently associated with presence of
damage after 18 months. Two further retrospective stud-
ies reported that patients with LLADS had a reduced
risk of damage accrual in at least half of observations
[13, 16]. Supported by our data and literature evi-
dence on damage development, we consider 7.5 mg/
day an acceptable cutoff to define low disease activity
during initial treatment, but A lower cutoff should be
targeted to minimize risk of steroid-related damage
during maintenance therapy in patients with SLE.
Renal involvement and serological disorders, consisting
of low complement and increased anti-dsDNA, had the
lowest remission rate in our cohort. However, renal in-
volvement at baseline was the most important factor asso-
ciated with failure to achieve LLDAS at 6 months (OR 7.8,
95% CI 1.4–43.4; p = 0.019) and 18 months (OR 3.9, 95%
CI 1.4–10.6; p = 0.008) from treatment initiation. In a
cross-sectional study, increased anti-dsDNA (OR 0.65,
95% CI 0.53–0.81; p < 0.001), renal involvement (OR 0.60,
95% CI 0.48–0.75; p < 0.001), low complement (OR 0.52,
95% CI 0.40–0.67; p < 0.001) shorter disease duration
(OR 0.31, 95% CI 0.19–0.49; p < 0.001) and history of
discoid rash (OR 0.66, 95% CI 0.49–0.89; p = 0.006)
were identified as negatively associated with LLDAS
[15]. These findings suggest that renal involvement
and serological abnormalities are associated with a
lower likelihood of LLDAS achievement.
Whether or not serological disorders should be
considered in the definition of minimal disease activity it
is a matter of debate [26]. Persistently increased anti-
dsDNA and low complement may be part of the sero-
logical active clinically quiescent (SACQ) disease pattern
[31], with some evidence suggesting a proportion of pa-
tients with SACQ disease can spend years without flares
[32] whilst other may relapse [33]. However, increasing-
fluctuating anti-dsDNA level rather than absolute values
can predict disease flares [34]. Thus, in order to enhance
the association between minimal acceptable disease activ-
ity and long-term outcomes, it would be conceivable to
consider rising levels of anti-dsDNA antibodies rather
than their steady positivity in the LLDAS definition.
This study has some limitations. First, the relatively small
sample size may have hampered the study results. Never-
theless, by enrolling consecutively diagnosed patients at the
time of treatment initiation and following them up pro-
spectively, we added some novel information on LLDAS as
a potential treatment target. Second, the retrospective
design of the study prevented us from testing LLDAS cri-
terion validity by comparing it with other treatment targets
such as the SLE Responder Index [35].
Conclusion
In conclusion, LLDAS is a promising treatment target in
SLE, being attainable and negatively associated with
damage accrual in the early stages of disease. However,
it seems to poorly fit with the heterogeneity of clinical
Table 3 Analysis of factors associated with any damage (SDI ≥1) at 18 months
Distribution of potential predictors of damage Multivariate analysis
SDI ≥1 (n = 23) SDI = 0 (n = 84) Odds ratio p value
No LLDAS at T1, n (%) 19 (82.6%) 41 (48.8%) 5.0 (1.5–16.6) 0.009
No LLDAS at T2, n (%) 18 (78.3%) 41 (48.8%) - -
Male gender, n (%) 3 (13.0%) 8 (9.5%) - -
Diagnosis age, median (IQR) years 39.4 (34.2–52.9) 31.9 (25.6–41.6) 1.05 (1.01–1.09) 0.020
Disease duration, median (IQR) months 9.9 (4.9–36.0) 9.6 (6.2–25.0) - -
Renal involvement, n (%) 9 (39.1%) 18 (21.4%) - -
PDN, mg/day median (IQR) 16.7 (11.0–23.2) 8.4 (5.0–16.7) - -
Anti-malarial drugs, n (%) 9 (39.1%) 57 (67.9%) - -
Immunosuppressant drugs, n (%) 17 (73.9%) 57 (67.9%) - -
SDI Systemic Lupus International Collaborating Clinic/Damage Index (SDI), No LLDAS failure to achieve the lupus low disease activity state, PDN prednisolone
(or equivalent)
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presentation in patients with SLE, mostly in those with
renal involvement. On the one hand, the poor LLDAS
attainability in patients with renal involvement could be
due to greater severity and lasting disease activity in the
renal domain. On the other hand, it could be due to the
unsuitability of LLDAS in capturing the minimal disease
activity in patients with renal involvement. Finally,
greater consensus should be reached on the definition of
serological disorders and prednisolone dose to be
included in a unique definition of minimally acceptable
disease activity.
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